Wim Vandenberghe1, Sofie Gevaert2, John A Kellum3, Sean M Bagshaw4, Harlinde Peperstraete1, Ingrid Herck1, Johan Decruyenaere1, Eric A J Hoste5. 1. Departments of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent, Belgium. 2. Departments of Cardiology, Ghent University Hospital, Ghent University, Ghent, Belgium. 3. Centre for Critical Care Nephrology, University of Pittsburgh, Pa., USA; The Clinical Research, Investigation, and Systems Modelling of Acute Illness (CRISMA) Centre, Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pa., USA. 4. Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta., Canada. 5. Departments of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent, Belgium; Research Foundation-Flanders (FWO), Brussels, Belgium; The Clinical Research, Investigation, and Systems Modelling of Acute Illness (CRISMA) Centre, Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pa., USA.
Abstract
BACKGROUND: We evaluated the epidemiology and outcome of acute kidney injury (AKI) in patients with cardiorenal syndrome type 1 (CRS-1) and its subgroups: acute heart failure (AHF), acute coronary syndrome (ACS) and after cardiac surgery (CS). SUMMARY: We performed a systematic review and meta-analysis. CRS-1 was defined by AKI (based on RIFLE, AKIN and KDIGO), worsening renal failure (WRF) and renal replacement therapy (RRT). We investigated the three most common clinical causes of CRS-1: AHF, ACS and CS. Out of 332 potential papers, 64 were eligible - with AKI used in 41 studies, WRF in 25 and RRT in 20. The occurrence rate of CRS-1, defined by AKI, WRF and RRT, was 25.4, 22.4 and 2.6%, respectively. AHF patients had a higher occurrence rate of CRS-1 compared to ACS and CS patients (AKI: 47.4 vs. 14.9 vs. 22.1%), but RRT was evenly distributed among the types of acute cardiac disease. AKI was associated with an increased mortality rate (risk ratio = 5.14, 95% CI 3.81-6.94; 24 studies and 35,227 patients), a longer length of stay in the intensive care unit [LOSICU] (median duration = 1.37 days, 95% CI 0.41-2.33; 9 studies and 10,758 patients) and a longer LOS in hospital [LOShosp] (median duration = 3.94 days, 95% CI 1.74-6.15; 8 studies and 35,227 patients). Increasing AKI severity was associated with worse outcomes. The impact of CRS-1 defined by AKI on mortality was greatest in CS patients. RRT had an even greater impact compared to AKI (mortality risk ratio = 9.2, median duration of LOSICU = 10.6 days and that of LOShosp = 20.2 days). KEY MESSAGES: Of all included patients, almost one quarter developed AKI and approximately 3% needed RRT. AHF patients experienced the highest occurrence rate of AKI, but the impact on mortality was greatest in CS patients.
BACKGROUND: We evaluated the epidemiology and outcome of acute kidney injury (AKI) in patients with cardiorenal syndrome type 1 (CRS-1) and its subgroups: acute heart failure (AHF), acute coronary syndrome (ACS) and after cardiac surgery (CS). SUMMARY: We performed a systematic review and meta-analysis. CRS-1 was defined by AKI (based on RIFLE, AKIN and KDIGO), worsening renal failure (WRF) and renal replacement therapy (RRT). We investigated the three most common clinical causes of CRS-1: AHF, ACS and CS. Out of 332 potential papers, 64 were eligible - with AKI used in 41 studies, WRF in 25 and RRT in 20. The occurrence rate of CRS-1, defined by AKI, WRF and RRT, was 25.4, 22.4 and 2.6%, respectively. AHF patients had a higher occurrence rate of CRS-1 compared to ACS and CS patients (AKI: 47.4 vs. 14.9 vs. 22.1%), but RRT was evenly distributed among the types of acute cardiac disease. AKI was associated with an increased mortality rate (risk ratio = 5.14, 95% CI 3.81-6.94; 24 studies and 35,227 patients), a longer length of stay in the intensive care unit [LOSICU] (median duration = 1.37 days, 95% CI 0.41-2.33; 9 studies and 10,758 patients) and a longer LOS in hospital [LOShosp] (median duration = 3.94 days, 95% CI 1.74-6.15; 8 studies and 35,227 patients). Increasing AKI severity was associated with worse outcomes. The impact of CRS-1 defined by AKI on mortality was greatest in CS patients. RRT had an even greater impact compared to AKI (mortality risk ratio = 9.2, median duration of LOSICU = 10.6 days and that of LOShosp = 20.2 days). KEY MESSAGES: Of all included patients, almost one quarter developed AKI and approximately 3% needed RRT. AHF patients experienced the highest occurrence rate of AKI, but the impact on mortality was greatest in CS patients.
Entities:
Keywords:
Acute kidney injury; Cardiorenal syndrome; Meta-analysis; Type 1
Authors: Robb D Kociol; Melissa A Greiner; Bradley G Hammill; Hemant Phatak; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez Journal: Am J Cardiol Date: 2010-04-27 Impact factor: 2.778
Authors: Andrew K Roy; Catherine Mc Gorrian; Cecelia Treacy; Edel Kavanaugh; Alice Brennan; Niall G Mahon; Patrick T Murray Journal: Cardiorenal Med Date: 2013-02-26 Impact factor: 2.041
Authors: Ainslie M Hildebrand; Arthur V Iansavichus; R Brian Haynes; Nancy L Wilczynski; Ravindra L Mehta; Chirag R Parikh; Amit X Garg Journal: Nephrol Dial Transplant Date: 2014-01-20 Impact factor: 5.992
Authors: Hussam F AlFaleh; Abdulkareem O Alsuwaida; Anhar Ullah; Ahmad Hersi; Khalid F AlHabib; Khalid AlNemer; Shukri AlSaif; Amir Taraben; Tarek Kashour; Mohammed A Balghith; Waqar H Ahmed Journal: Int J Cardiol Date: 2012-02-19 Impact factor: 4.164
Authors: Powell Jose; Hicham Skali; Nagesh Anavekar; Charles Tomson; Harlan M Krumholz; Jean L Rouleau; Lemuel Moye; Marc A Pfeffer; Scott D Solomon Journal: J Am Soc Nephrol Date: 2006-08-23 Impact factor: 10.121
Authors: Lars Englberger; Rakesh M Suri; Zhuo Li; Edward T Casey; Richard C Daly; Joseph A Dearani; Hartzell V Schaff Journal: Crit Care Date: 2011-01-13 Impact factor: 9.097
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Mizuko Ikeda; Rumie Wakasaki; Katie J Schenning; Thomas Swide; Jeong Heon Lee; M Bernie Miller; Hak Soo Choi; Sharon Anderson; Michael P Hutchens Journal: Am J Physiol Renal Physiol Date: 2017-01-11
Authors: Rumie Wakasaki; Katsuyuki Matsushita; Kirsti Golgotiu; Sharon Anderson; Mahaba B Eiwaz; Daniel J Orton; Sang Jun Han; H Thomas Lee; Richard D Smith; Karin D Rodland; Paul D Piehowski; Michael P Hutchens Journal: JCI Insight Date: 2019-02-21
Authors: Neil A Hukriede; Danielle E Soranno; Veronika Sander; Tayla Perreau; Michelle C Starr; Peter S T Yuen; Leah J Siskind; Michael P Hutchens; Alan J Davidson; David M Burmeister; Sarah Faubel; Mark P de Caestecker Journal: Nat Rev Nephrol Date: 2022-02-16 Impact factor: 42.439
Authors: Ana Flávia Lima Ruas; Gabriel Malheiros Lébeis; Nicholas Bianco de Castro; Vitória Andrade Palmeira; Larissa Braga Costa; Katharina Lanza; Ana Cristina Simões E Silva Journal: Pediatr Nephrol Date: 2021-11-30 Impact factor: 3.651
Authors: Nathan M Lee; Lev Deriy; Timothy R Petersen; Vallabh O Shah; Michael P Hutchens; Neal S Gerstein Journal: J Cardiothorac Vasc Anesth Date: 2018-08-01 Impact factor: 2.894